Author

H. E. Bergom

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Day· 2 shared J. H. Hwang· 2 shared J. M. Drake· 2 shared M. Ludwig· 2 shared A. Ali· 1 shared A. T. Cheung· 1 shared C. Ilsa· 1 shared C. Richter· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Day

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts

Z. E. Sychev, A. Day, H. E. Bergom, G. Larson, A. Ali, M. Ludwig, E. Boytim, C. Ilsa, E. Corey, S. R. Plymate, P. S. Nelson, J. H. Hwang, J. M. Drake

The paper characterizes the proteome and phosphoproteome of prostate cancer patient-derived xenografts to identify differences between neuroendocrine-like and adenocarcinoma subtypes.

bioRxiv · Aug 2, 2023Cancer Biology

Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer

R. E. White, M. Bannister, A. Day, H. E. Bergom, V. M. Tan, J. Hwang, H. D. Nguyen, J. Drake

This study shows that combining saracatinib with enzalutamide reduces androgen receptor activity and DNA replication in CRPC cell lines, leading to increased apoptosis.

bioRxiv · Apr 22, 2023 · PreprintCancer Biology

CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies

J. H. Hwang, R. Arafeh, J.-H. Seo, S. C. Baca, M. Ludwig, T. E. Arnoff, C. Richter, H. E. Bergom, S. McSweeney, J. P. Rennhack, S. A. Klingenberg, A. T. Cheung, J. Kwon, J. So, S. Kregel, , W. Hahn

This study identifies CREB5 as a key driver of resistance to androgen receptor targeting therapies by reprogramming nuclear interactions and activating TGFβ and Wnt signaling pathways.

bioRxiv · Aug 18, 2021Cancer Biology